Bowel cancer study reveals impact of mutations on protein networks

The results offer clearer picture of the cellular processes behind bowel cancer, and may enable future tailoring of drug treatments to different bowel cancer patients

Consequences of Mutations on Protein Complexes. 
Correlations networks filtered for known STRING interactions of proteins downregulated by LoF mutations at p value < 0.05. The font size is proportional to the log10(p value). CORUM interactions are highlighted as green thick edges, and representative protein complexes are labeled. Credit: Cell Reports DOI: 10.1016/j.celrep.2017.08.010
For the first time, scientists have completed a detailed study of many of the proteins in bowel cancer cells. Scientists from the Wellcome Trust Sanger Institute investigated the role proteins play in predicting how common mutations affect proteins in the cancer cells and also whether such proteins are important in predicting the cancer’s response to treatment.

The results, published today (29 August) in Cell Reports give scientists a better picture of the cellular processes behind bowel cancer, and could enable researchers to predict which drugs would be effective in treating different bowel cancer patients.

Every day, 110 people are diagnosed with bowel cancer. There are around 41,300 new cases of the disease each year, and it is the fourth most common cancer in the UK*.

To understand the biology underlying cancer, scientists have traditionally studied all of the cancer genes – the genome – and all of the RNA – the transcriptome – in the cancer. However, a blindspot in research has been the study of all of the proteins – the proteome – and it is the proteins that are the building blocks of cell machinery.

In the new study, scientists conducted a very deep, detailed study of the proteins in bowel cancer to investigate whether proteins play a role in predicting the effect of different drugs against the cancer. The researchers analysed 9,000 proteins for each of 50 bowel cancer cell lines.

“This study is the first detailed characterisation of colorectal cancer cell lines. It is important to include the proteome in cancer research because proteins are the building blocks of life, and networks of proteins working together are known to drive fundamental processes in cancer. The proteome contains unique information on cell organisation and function. Just studying the genome and transcriptome in the past has proven to be a blindspot in cancer research – but now including the proteome, we have the full picture.”

Dr Jyoti Choudhary Lead author from the Wellcome Trust Sanger Institute and The Institute of Cancer Research, London

The team were able to construct co-ordinated networks of proteins that drive bowel cancer. Researchers used CRISPR-Cas9 to disrupt, or knock out, a single gene that encoded a key protein, and see the effects on the proteins in the rest of its network.

“We discovered that silencing one gene has consequences on the rest of the network, lessening the amount of other proteins – like a ripple effect. We have identified many pathways within the protein network that could be targeted with drugs for bowel cancer, which we could only discover by studying the proteome.”

Dr Theodoros Roumeliotis First author from the Wellcome Trust Sanger Institute

In the study, the team tested 265 existing anti-cancer drugs on the 50 bowel cancer cell lines. Details of the genome and transcriptome have previously been used to predict which drugs would work in particular cancer cases, however the activity of some drugs could not be predicted.

By studying the proteome the team could predict drug responses that weren’t explained by either genomics or transcriptomics.

“This study is promising for bowel cancer patients. It confirms that this common cancer is actually composed of five different subtypes that may require different drug treatments, and surprisingly suggests that proteins may be more predictive for drug sensitivity than we have previously thought. In the future we may need to test the patient’s genome, transcriptome and proteome to fully predict their response to cancer drugs and stratify patients for clinical trials more effectively. We are moving away from one size fits all towards personalised medicine.”

Dr Ultan McDermott Senior author from the Wellcome Trust Sanger Institute

Press Contact

If you need help or have any queries, please contact us using the details below.

Emily Mobley
Media Manager
Tel +44 (0)1223 496 851
Email: emily.mobley@sanger.ac.uk

 

Dr Matthew Midgley
Media Officer
Tel +44 (0)1223 494 856
Email: matthew.midgley@sanger.ac.uk

 

Dr Samantha Wynne
Media Officer
Tel +44 (0)1223 492 368
Email: samantha.wynne@sanger.ac.uk

 

Press office
Wellcome Sanger Institute, Hinxton,
Cambridgeshire, CB10 1SA, UK
Tel +44 (0) 7748 379849
Email: press.office@sanger.ac.uk

 

Notes to Editor

Sources

* http://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/bowel-cancer#heading-Zero

Funding:

This work was supported by Wellcome and the European Research Council.

Publications:

Loading publications...

Selected websites

  • The Institute of Cancer Research, London

    The Institute of Cancer Research, London, is one of the world’s most influential cancer research organisations.

    Scientists and clinicians at The Institute of Cancer Research (ICR) are working every day to make a real impact on cancer patients’ lives. Through its unique partnership with The Royal Marsden NHS Foundation Trust and ‘bench-to-bedside’ approach, the ICR is able to create and deliver results in a way that other institutions cannot. Together the two organisations are rated in the top four centres for cancer research and treatment globally.

    The ICR has an outstanding record of achievement dating back more than 100 years. It provided the first convincing evidence that DNA damage is the basic cause of cancer, laying the foundation for the now universally accepted idea that cancer is a genetic disease. Today it is a world leader at identifying cancer-related genes and discovering new targeted drugs for personalised cancer treatment.

    A college of the University of London, the ICR is the UK’s top-ranked academic institution for research quality, and provides postgraduate higher education of international distinction. It has charitable status and relies on support from partner organisations, charities and the general public.

    The ICR’s mission is to make the discoveries that defeat cancer. For more information visit http://www.icr.ac.uk

  • The Wellcome Trust Sanger Institute

    The Wellcome Trust Sanger Institute is one of the world’s leading genome centres. Through its ability to conduct research at scale, it is able to engage in bold and long-term exploratory projects that are designed to influence and empower medical science globally. Institute research findings, generated through its own research programmes and through its leading role in international consortia, are being used to develop new diagnostics and treatments for human disease.

  • Wellcome

    Wellcome exists to improve health for everyone by helping great ideas to thrive. We’re a global charitable foundation, both politically and financially independent. We support scientists and researchers, take on big problems, fuel imaginations and spark debate.